WEBULL
WebtradeDownload

Learn Why The Bull Case For Viridian Therapeutics Stock Could Change Following FDA Approval

Simply Wall St · 1d ago
  • Viridian Therapeutics secured FDA approval in June 2026 for Lumvoa to treat both active and chronic thyroid eye disease, and moved straight into commercial launch in the United States.
  • The approval gives Viridian Therapeutics its first marketed IGF-1R therapy in a roughly US$2b thyroid eye disease market that currently appears only lightly penetrated by this drug class.
  • We will look at how Viridian Therapeutics' investment narrative evolves as Lumvoa's rapid FDA approval and launch reshape its commercial profile.

Scan similar early commercial stories in healthcare and biotech with the handpicked 19 high quality undiscovered gems that echo what Viridian Therapeutics is trying to achieve with Lumvoa in thyroid eye disease.

Viridian Therapeutics Investment Narrative Recap

For a shareholder in Viridian Therapeutics, the core belief is that Lumvoa can anchor a thyroid eye disease franchise in a roughly US$2b market that still looks early in its use of IGF-1R drugs. The rapid FDA approval and immediate US launch make commercial execution on Lumvoa the key near term catalyst, because it now needs to convert clinical data into treated patients.

The flip side is operational risk. Viridian Therapeutics is still loss making, with analysts expecting a very large swing in margins and earnings over the next few years, plus ongoing share dilution. If the Lumvoa roll out proves slower or more expensive than expected, the market could reassess those aggressive assumptions quite quickly.

The most relevant development tied to this quarter’s fund activity is the Lumvoa approval and launch in late June. This turns Viridian Therapeutics from a pure development story into a commercial business, and puts real weight on payer access, the effectiveness of its roughly 100 person sales force, and how fast buy and bill uptake builds.

Every future catalyst now sits on top of that operational base. The planned BLA submission for elegrobart in 2027, the broader autoimmune pipeline and the use of the US$350m plus capital raises all matter, but their value will be judged through the lens of Lumvoa execution, cash burn, and the path toward the profitability inflection analysts are currently modeling.

Viridian Therapeutics' narrative projects US$741.1 million revenue and US$84.9 million earnings by 2029. This rests on analysts assuming 118.4% yearly revenue growth and an earnings swing of roughly US$419 million, from a loss of US$334.0 million today to forecast consensus earnings of US$84.9 million.

Discover why Viridian Therapeutics' fair value suggests a 45% potential upside to its current price, an opportunity that may narrow quickly.

NasdaqCM:VRDN 1-Year Stock Price Chart
NasdaqCM:VRDN 1-Year Stock Price Chart

Exploring Other Perspectives

For Viridian Therapeutics, the alternate story puts near term Lumvoa revenue risk front and center. Before this FDA approval and launch, the lowest analysts were only penciling in about US$448.2 million of revenue and US$71.7 million of earnings for 2029. That is a much more cautious script. Use this news as a prompt to compare these different forecasts directly.

Explore 3 other Viridian Therapeutics fair value estimates, including one that suggests it could be worth just $36.20!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more Viridian Therapeutics style ideas?

If the Viridian Therapeutics story has prompted you to widen your watchlist, the Simply Wall St Screener can help you find other companies with traits that match your own risk and return preferences.

  • For investors who want quality at a discount, scan a curated set of stronger fundamentals with the 34 high quality undervalued stocks and see which businesses currently line up with your valuation filters.
  • If capital preservation sits high on your checklist, focus on resilience first and growth second by reviewing the 29 resilient stocks with low risk scores that screens for companies with lower overall risk scores.
  • When balance sheet strength matters more to you than story or hype, filter for sturdier finances using the list of solid balance sheet and fundamentals (24 results) and look for businesses that pair financial stability with consistent execution.